Stay updated on Pembrolizumab in Hypermutation Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Hypermutation Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The updated screenshots show cosmetic UI adjustments with no changes to core trial information (status, enrollment, eligibility, outcomes). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T09:51:51.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    34 days ago
    Change Detected
    Summary
    Adds a current operating-status notice, a verified status entry with a date, and a new revision (v3.2.0); removes the old status and previous revision (v3.1.0).
    Difference
    3%
    Check dated 2025-10-05T14:22:57.000Z thumbnail image
  4. Check
    42 days ago
    Change Detected
    Summary
    Updated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.
    Difference
    0.1%
    Check dated 2025-09-28T09:46:56.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2, indicating a new release. The 'Back to Top' link was removed as a minor UI change.
    Difference
    0.1%
    Check dated 2025-09-14T00:17:45.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.1%
    Check dated 2025-09-06T21:17:05.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has been updated to include new therapeutic topics related to colorectal cancer, specifically mentioning pembrolizumab and neoadjuvant therapy, while also changing the facility name and location to Milan, Italy.
    Difference
    2%
    Check dated 2025-08-30T15:37:43.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Hypermutation Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Hypermutation Clinical Trial page.